A new compound, called VU319, has delivered promising results in a Phase 1 trial for treating Alzheimer's disease and other neudegenerative conditions. | Drug Discovery And Development ...

To design safe and effective drugs, the pharmacology of how drugs work in relationship to the body must be understood. This ...

Researchers at Tel Aviv University have developed a new platform using polymeric nanoparticles to deliver drug pairs to ...

The researchers developed nanoparticles, which dissolve into water and carbon dioxide within a month, to encapsulate two ...

We found that drug pairs delivered this way significantly enhanced their therapeutic effect in BRAF-mutated skin cancers and BRCA-mutated breast cancers and their brain metastases.” ...

Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer's and other neurodegenerative diseases. The compound, named VU319, is the first end-to-end drug discovery ...

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug ...

"This breakthrough is a big step forward in developing new malaria treatments," Yu said. "By focusing on PfNCR1, scientists could develop drugs that the parasite finds difficult to develop resistance ...

Malaria, caused by a parasite transmitted to humans through an infected mosquito's bite, is a leading cause of illness and ...

A 10-panel drug test is a common way to check for various drugs in a person’s body. It typically involves testing urine for drugs, such as cannabinoids, opioids, and more. Typically, traces of ...